Literature DB >> 24381091

The validity and reliability of the Persian version of the Revised Fibromyalgia Impact Questionnaire.

Banafsheh Ghavidel Parsa1, Alireza Amir Maafi, Afrooz Haghdoost, Yasaman Arabi, Monire Khojamli, Gelayol Chatrnour, Ali Bidari.   

Abstract

The Revised Fibromyalgia Impact Questionnaire (FIQR), an updated version of the Fibromyalgia Impact Questionnaire (FIQ) achieved a better balance among different domains (i.e., function, overall impact, and symptom severity) and attempts to address the limitations of FIQ. As there is no Persian version of the FIQR available, we aimed to investigate the validity and reliability of a Persian translation of the FIQR in Iranian patients. After translating the FIQR into Persian, it was administered to 77 female patients with fibromyalgia syndrome. All of the patients filled out the questionnaire together with a Persian version of the FIQ, short form-12 (SF-12). The tender-point count was also calculated. One week later, FM patients filled out the Persian FIQR at their second visit. Reliability was analyzed by internal consistency and reproducibility including Cronbach's α coefficient and intra-class correlation coefficient. Construct validity was evaluated by Spearman's correlation coefficient and Pearson's correlation coefficient. Statistical analysis was performed using SPSS for Windows version 17.0. All patients included in this study were female, and the mean age was 38.23 ± 10.68 years. The total scores of the FIQR and FIQ were 49.77 ± 18.27 and 54.05 ± 14.00 that were closely correlated (r = 0.63, p < 0.01), and each of the three domains of the Persian FIQR was also correlated well with the three related FIQ domains (r = 0.36-0.63, p < 0.01). Also some significant inverse correlations of FIQR with quality-of-life (assessed by SF-12) domains and items were found. Cronbach's α was 0.87 for FIQR in the first visit. The Persian FIQR showed adequate reliability and validity. This instrument can be used in the clinical evaluation of Iranian patients with fibromyalgia.

Entities:  

Mesh:

Year:  2014        PMID: 24381091     DOI: 10.1007/s00296-013-2929-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  18 in total

Review 1.  Are the contents of treatment outcomes in fibromyalgia trials represented in the International Classification Of Functioning, Disability, and Health?

Authors:  Martin Offenbächer; Alarcos Cieza; Thomas Brockow; Edda Amann; Barbara Kollerits; Gerold Stucki
Journal:  Clin J Pain       Date:  2007-10       Impact factor: 3.442

2.  The validity and reliability of the Moroccan version of the Revised Fibromyalgia Impact Questionnaire.

Authors:  Najlaa Srifi; Rachid Bahiri; Samira Rostom; Imad Bendeddouche; Noufissa Lazrek; Najia Hajjaj-Hassouni
Journal:  Rheumatol Int       Date:  2013-01       Impact factor: 2.631

3.  Validation of the 2010 American College of Rheumatology preliminary diagnostic criteria for fibromyalgia in an Iranian population.

Authors:  Ali Bidari; Morteza Hassanzadeh; Banafsheh Ghavidel Parsa; Nahid Kianmehr; Ali Kabir; Sara Pirhadi; Mohammad Sayfi; Mehrangiz Toutounchi; Fariba Fattahi; Fereidoon Zandi Karimi
Journal:  Rheumatol Int       Date:  2013-07-25       Impact factor: 2.631

4.  The validity and reliability of the Turkish version of the Revised Fibromyalgia Impact Questionnaire.

Authors:  Levent Ediz; Ozcan Hiz; Murat Toprak; Ibrahım Tekeoglu; Songul Ercan
Journal:  Clin Rheumatol       Date:  2010-08-12       Impact factor: 2.980

5.  Outcome and predictor relationships in fibromyalgia and rheumatoid arthritis: evidence concerning the continuum versus discrete disorder hypothesis.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  J Rheumatol       Date:  2009-02-17       Impact factor: 4.666

6.  The fibromyalgia impact questionnaire: development and validation.

Authors:  C S Burckhardt; S R Clark; R M Bennett
Journal:  J Rheumatol       Date:  1991-05       Impact factor: 4.666

7.  The prevalence and characteristics of fibromyalgia in the general population.

Authors:  F Wolfe; K Ross; J Anderson; I J Russell; L Hebert
Journal:  Arthritis Rheum       Date:  1995-01

8.  Fibromyalgia syndrome.

Authors:  Philip Mease; Lesley M Arnold; Robert Bennett; Annelies Boonen; Dan Buskila; Serena Carville; Amy Chappell; Ernest Choy; Daniel Clauw; Dina Dadabhoy; Michael Gendreau; Don Goldenberg; Geoffrey Littlejohn; Susan Martin; Philip Perera; I Jon Russell; Lee Simon; Michael Spaeth; David Williams; Leslie Crofford
Journal:  J Rheumatol       Date:  2007-06       Impact factor: 4.666

9.  Validation of a Persian version of the Fibromyalgia Impact Questionnaire (FIQ-P).

Authors:  Ali Bidari; Morteza Hassanzadeh; Mohamad-Farzam Mohabat; Elham Talachian; Effat Merghati Khoei
Journal:  Rheumatol Int       Date:  2013-10-29       Impact factor: 2.631

10.  An internet survey of 2,596 people with fibromyalgia.

Authors:  Robert M Bennett; Jessie Jones; Dennis C Turk; I Jon Russell; Lynne Matallana
Journal:  BMC Musculoskelet Disord       Date:  2007-03-09       Impact factor: 2.362

View more
  9 in total

1.  Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial.

Authors:  Ali Bidari; Ehsan Moazen-Zadeh; Banafsheh Ghavidel-Parsa; Shahrzad Rahmani; Sajjad Hosseini; Amir Hassankhani
Journal:  Daru       Date:  2019-03-14       Impact factor: 3.117

Review 2.  Are OMERACT recommendations followed in clinical trials on fibromyalgia? A systematic review of patient-reported outcomes and their measures.

Authors:  Annika Döhmen; Milan Kock; Alexander Obbarius; Christoph Paul Klapproth; Felix Fischer; Matthias Rose
Journal:  Qual Life Res       Date:  2022-10-01       Impact factor: 3.440

Review 3.  The Iceberg Nature of Fibromyalgia Burden: The Clinical and Economic Aspects.

Authors:  Banafsheh Ghavidel-Parsa; Ali Bidari; Alireza Amir Maafi; Babak Ghalebaghi
Journal:  Korean J Pain       Date:  2015-07-01

4.  Serum Vitamin D Status in Iranian Fibromyalgia Patients: according to the Symptom Severity and Illness Invalidation.

Authors:  Alireza Amir Maafi; Banafsheh Ghavidel-Parsa; Afrooz Haghdoost; Yasaman Aarabi; Asghar Hajiabbasi; Irandokht Shenavar Masooleh; Habib Zayeni; Babak Ghalebaghi; Amir Hassankhani; Ali Bidari
Journal:  Korean J Pain       Date:  2016-07-01

5.  Implication of the Nociplastic Features for Clinical Diagnosis of Fibromyalgia: Development of the Preliminary Nociplastic-Based Fibromyalgia Features (NFF) Tool.

Authors:  Banafsheh Ghavidel-Parsa; Ali Bidari; Zahra Atrkarroushan; Mohammad-Javad Khosousi
Journal:  ACR Open Rheumatol       Date:  2021-12-22

6.  Comparison of the serum brain-derived neurotrophic factor (BDNF) between fibromyalgia and nociceptive pain groups; and effect of duloxetine on the BDNF level.

Authors:  Ali Bidari; Banafsheh Ghavidel-Parsa; Faeze Gharibpoor
Journal:  BMC Musculoskelet Disord       Date:  2022-05-02       Impact factor: 2.562

7.  Validity and reliability of the Persian version of illness invalidation inventory (3*I) among patients with non-inflammatory rheumatic painful disorders.

Authors:  Banafsheh Ghavidel-Parsa; Mohammad-Javad Khosousi; Sepehr Tohidi; Ali Bidari; Saman Soltani; Habib Zayeni; Ali Montazeri
Journal:  BMC Rheumatol       Date:  2022-05-03

8.  Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial.

Authors:  Mansoor Shakiba; Ehsan Moazen-Zadeh; Ahmad Ali Noorbala; Morteza Jafarinia; Parisa Divsalar; Ladan Kashani; Nazila Shahmansouri; Abbas Tafakhori; Hannaneh Bayat; Shahin Akhondzadeh
Journal:  Avicenna J Phytomed       Date:  2018 Nov-Dec

9.  Effect of Crocus sativus (Saffron) Intake on Top of Standard Treatment, on Disease Outcomes and Comorbidities in Patients with Rheumatic Diseases: Synthesis without Meta-Analysis (SWiM) and Level of Adherence to the CONSORT Statement for Randomized Controlled Trials Delivering Herbal Medicine Interventions.

Authors:  Sotirios G Tsiogkas; Maria G Grammatikopoulou; Konstantinos Gkiouras; Efterpi Zafiriou; Iordanis Papadopoulos; Christos Liaskos; Efthimios Dardiotis; Lazaros I Sakkas; Dimitrios P Bogdanos
Journal:  Nutrients       Date:  2021-11-27       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.